Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab, Gemcitabine, and Carboplatin for Cisplatin-Ineligible MIBC (GAP Trial)
NCT04871529Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, sponsored by SWOG Cancer Research Network. Started Aug 2022; status: terminated.
02
Drugs
avelumab
Beyond the preview
Go deeper on NCT04871529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871529.